MedPath

ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD

🇨🇳China
Ownership
-
Established
1998-02-11
Employees
2.9K
Market Cap
-
Website
www.hisunpharm.com
Introduction

The company was founded in 1956 and was listed on A-shares in 2000. In 2012, Haizheng Pfizer Pharmaceuticals Co., Ltd. was established as a joint venture with Pfizer in the field of branded generic drugs. Selected as the country's first batch of “Innovative Enterprises”, “National Intellectual Property Demonstration Enterprises”, and “National Industrial Brand Cultivation Demonstration Enterprises”, and included in the “National Top 100 Pharmaceutical Industry Enterprises”, “China's Top 100 Chemical and Pharmaceutical Industry Industrial Enterprises with Comprehensive Strength”, and “2017 Top 100 Pharmaceutical Internationalization Enterprises”. The company's API business mainly includes traditional self-produced API export business, API contract customization business for global pharmaceutical companies, and domestic sales business. The company's main products are: injectable piperacillin sodium and tazobactam sodium (tetracycline), minocycline hydrochloride capsules (Hemman), amlodipine atorvastatin calcium tablets (up to 1), sirolimus tablets (rapamine), rosofastatin calcium tablets (hisuyan), injectable methylprednisolone sodium succinate (methanolone), injectable adenosylmethionine (Ximexin), orlistat, etc. Corporate honors: It has won honors such as “National High-tech Enterprise” and “National May 1st Labor Award”, and has been selected for honorary titles such as the country's first batch of “Innovative Enterprises”, “National Intellectual Property Demonstration Enterprise”, and the Zhejiang Provincial Government Quality Award.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

228

NMPA:228

Drug Approvals

Posaconazole Injection

Product Name
泊沙康唑注射液
Approval Number
国药准字H20253842
Approval Date
Apr 8, 2025
NMPA

Everolimus Tablets

Product Name
依维莫司片
Approval Number
国药准字H20253002
Approval Date
Jan 2, 2025
NMPA

Rifampin Isoniazid and Pyrazinamide Tablets

Product Name
依比福
Approval Number
国药准字H20031049
Approval Date
Sep 20, 2024
NMPA

Posaconazole Enteric-coated Tablets

Product Name
泊沙康唑肠溶片
Approval Number
国药准字H20244926
Approval Date
Sep 19, 2024
NMPA

Mitomycin

Product Name
丝裂霉素
Approval Number
国药准字H33020854
Approval Date
Sep 14, 2024
NMPA

Pipemidic Acid Tablets

Product Name
吡哌酸片
Approval Number
国药准字H33021731
Approval Date
Sep 14, 2024
NMPA

Granisetron Hydrochloride Capsules

Product Name
安斯平
Approval Number
国药准字H20030584
Approval Date
Sep 12, 2024
NMPA

Meropenem

Product Name
美罗培南
Approval Number
国药准字H20030330
Approval Date
Sep 10, 2024
NMPA

Glucosamine Sulfate and Sodium Chloride Component Salts

Product Name
硫酸氨基葡萄糖氯化钠复盐
Approval Number
国药准字H20041315
Approval Date
Sep 3, 2024
NMPA

Isepamicin Sulfate

Product Name
硫酸异帕米星
Approval Number
国药准字H20045999
Approval Date
Sep 3, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 23
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.